Cellply Fringe Event: Session 5

Cellply Fringe Event: Session 5

Thursday, January 18, 2024 5:00 PM to 5:45 PM · 45 min. (US/Eastern)
Fringe Event
Presentation
Exhibitor Booth 427

Information

17:00 – 17:15 Advancing Translational Studies Of NK Cell-Based Therapies Using Insights From Multiparametric And Single-Cell Serial Killing Analysis To Inform Novel Treatment Strategies

  • Identifying subpopulations of educated serial-killer NK cells as a means to optimize donor selection and enhance anti-tumor activity
  • Goal to enable the correlation of clinical outcome with potency assessment of circulating immune cells in treated patients

Evren Alici, Co-Director of Next Generation NK Cell Competence Center, Karolinska Institutet

17.15 - 17.30 Break

17.30 - 17.45 Linking In-Vitro Analysis Of Function And Phenotype For Deep Characterization Of Cell Therapy At The Single-Cell Level

  • Single-cell multiparametric analysis enhances understanding of immunotherapy mode of action
  • Analysis of cytotoxicity and phenotype reveals immune cell functional heterogeneity, i.e. “which cells do what” and provides actionable data to support discovery and process development

Massimo Bocchi, Chief Strategy Officer, Cellply

Cellply427Cellply - Unravelling immune system function, one cell at a time. Functional profiling at single cell resolution within a heterogenous cell population offers a unique signature into cellular interactions. Our powerful, fully automated VivaCyte platform delivers in-depth comprehensive characterization of immune cell function for cytotoxicity, serial killing and cytokine secretion assays in combination with phenotypic analysis. Employing propriety co-culture array technology and AI informed imaging, our multi-parametric single-cell analysis provides actionable insights across research and development. VivaCyte offers a dramatically improved level of understanding of immunotherapy mode of action, including determination of relative potency.

Log in